{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T15:41:23Z","timestamp":1746114083769},"reference-count":42,"publisher":"Hindawi Limited","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3728,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00585.x","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T16:03:12Z","timestamp":1119024192000},"page":"831-838","source":"Crossref","is-referenced-by-count":11,"title":["Darifenacin in the treatment of overactive bladder"],"prefix":"10.1155","volume":"59","author":[{"given":"M.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2005,6,17]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB1|cit1","unstructured":"Health Survey Questionnaire. Southwark Street 1990 95"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"10.1111\/j.1368-5031.2005.00585.x-BIB3|cit3","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficency of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB5|cit5","first-page":"S66","article-title":"Prevalence of overactive bladder in women: results from the NOBLE program","volume":"12","author":"Stewart","year":"2001","journal-title":"Int Urogyn J"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB7|cit7","unstructured":"Brown JS."},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/bmj.282.6270.1103","article-title":"Clinical and urodynamic studies in 100 elderly women","volume":"282","author":"Castleden","year":"1981","journal-title":"Br Med J Clin Res Ed"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB9|cit9","first-page":"279","article-title":"International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1569-9056(02)00045-3","article-title":"Potential benefits of Muscarinic M3 Receptor Selectivity","volume":"1","author":"Andersson","year":"2002","journal-title":"Eur Urol Suppl"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-5347(01)67039-3","article-title":"Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells","volume":"154","author":"Harriss","year":"1995","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0022-5347(01)65752-5","article-title":"Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle","volume":"156","author":"Yamaguchi","year":"1996","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB13|cit13","first-page":"1654","article-title":"The M2 receptor contributes to contraction of the denervated rat urinary bladder","volume":"275","author":"Braverman","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB14|cit14","unstructured":"Napier C Gupta P."},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/1043-6618(95)86474-1","article-title":"Darifenacin, a selective muscarinic M3 antagonist","volume":"31S","author":"Wallis","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB16|cit16","first-page":"198P","article-title":"In vivo profile of darifenacin, a selective muscarinic M3 receptor antagonist","volume":"119","author":"Quinn","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00585.x-BIB17|cit17","article-title":"The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat [abstract, 205P]","volume":"120","author":"Williamson","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB18|cit18","unstructured":"Mundy AR Abrams P Chapple CR Neal DE"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB19|cit19","unstructured":""},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/01.ju.0000148963.21096.5d","article-title":"Assessment of cognitive function of the elderly population: effects of darifenacin","volume":"173","author":"Lipton","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB21|cit21","article-title":"Darifenacin demonstrated no adverse effect on cognitive and cardiac function: results from a double-blind, randomised, placebo-controlled study","volume":"20","author":"Nichols","year":"2001","journal-title":"Neurourol Urodyn"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00585.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1569-9056(02)80508-5","article-title":"In vivo bladder selectivity of darifenacin, a new M3 antimuscarinic agent, in the anaesthetised dog [abstract, 515]","volume":"1","author":"Gupta","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/004982598239768","article-title":"Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man","volume":"28","author":"Beaumont","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2125.2003.01967.x","article-title":"Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability","volume":"56","author":"Kerbusch","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB25|cit25","first-page":"1552","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB26|cit26","first-page":"89","article-title":"No effect of food on pharmacokinetics of darifenacin in multiple doses","volume":"1","author":"Nichols","year":"2001","journal-title":"Pharmacol Toxicol Suppl"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2125.2003.01988.x","article-title":"Assessment of the relative in vivo potency of the. hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data","volume":"57","author":"Kerbusch","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical significance","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl. 3","key":"10.1111\/j.1368-5031.2005.00585.x-BIB30|cit30","first-page":"S32","article-title":"Darifenacin does not affect the pharmacokinetics of a combined oral contraceptive (Microgynon\u00ae) in healthy women","volume":"12","author":"Salvatore","year":"2001","journal-title":"Int Urogynecol J"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarine M3 selective receptor antogonist, in the treatment of overactive bladder","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/nau.1930120604","article-title":"Computerised voiding diary","volume":"12","author":"Rabin","year":"1993","journal-title":"Neurourol Urodyn"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00585.x-BIB33|cit33","first-page":"126","article-title":"Efficacy and tolerability of darifenacin, a muscarinic M3 receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder","volume":"94","author":"Zinner","year":"2004","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00585.x-BIB35|cit35","first-page":"126","article-title":"Quality of life effects of darifenacin, an M3 selective receptor antagonist, in patients with overactive bladder","volume":"94","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00585.x-BIB36|cit36","first-page":"S126","article-title":"Darifenacin a highly M3 selective receptor antagonist is effective and well tolerated by elderly patients with overactive bladder","volume":"52","author":"Foote","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0197-4572(80)80041-3","article-title":"Recognizing warning time: a critical step toward continence","volume":"1","author":"Chalifoux","year":"1980","journal-title":"Geriatr Nurs"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/01.ju.0000155798.78911.57","article-title":"Increased warning time with darifenacin: a new concept in the management of urinary urgency","volume":"173","author":"Cardozo","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB39|cit39","first-page":"291","article-title":"Darifenacin: An M3-selective muscarinic antagonist for the treatment of overactive bladder","volume":"39","author":"Kirwin","year":"2004","journal-title":"Formulary"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00585.x-BIB40|cit40","article-title":"Central nervous system (CNS)-related adverse events in patients with overactive bladder (OAB) treated with darifenacin versus tolterodine","volume":"94","author":"Foote","year":"2004","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1464-410X.2005.05343.x","article-title":"An investigation of dose tritation with darifenacin, an M3 selective receptor antogonist","volume":"95","author":"Steers","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00585.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00002512-200421130-00005","article-title":"Darifenacin: in the treatment of overactive bladder","volume":"21","author":"Croom","year":"2004","journal-title":"Drugs Aging"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00585.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00585.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:43Z","timestamp":1643349943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00585.x"}},"subtitle":["Darifenacin In The Treatment Of Overactive Bladder"],"short-title":[],"issued":{"date-parts":[[2005,6,17]]},"references-count":42,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00585.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6,17]]}}}